Renal denervation isn't dead, despite Medtronic trial's failure

The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.

Boston Scientific, Covidien, Kona Medical, Medtronic, ReCor Medical, St. Jude Medical

News Well, Clinical Trials, Hypertension, Renal, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1x5qgvP